Related Experiment Video
Updated: Aug 11, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Extended-release niacin for modifying the lipoprotein profile
1Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA. john.guyton@duke.edu
Expert Opinion on Pharmacotherapy
|May 28, 2004
Summary
Extended-release niacin (niacin ER) effectively improves lipid profiles and clinical outcomes with fewer side effects than other niacin formulations. This makes niacin ER a safe option for managing dyslipidemia, even in diabetic patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Niacin (nicotinic acid) is known to favorably impact lipoprotein profiles, including raising HDL-C and lowering LDL-C and triglycerides.
- Traditional immediate-release niacin (niacin IR) is limited by flushing, while sustained-release (SR) formulations carry risks of hepatotoxicity.
- Extended-release niacin (niacin ER) was developed to improve tolerability and safety profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of extended-release niacin (niacin ER) in managing dyslipidemia.
- To compare niacin ER with immediate-release niacin (niacin IR) and sustained-release (SR) formulations.
- To assess the safety of niacin ER in combination therapy and in diabetic patients.
Main Methods:
- Review of clinical trials investigating niacin ER for lipid modification and clinical outcomes.
- Comparison of niacin ER's efficacy and side effect profile against niacin IR and SR formulations.
- Assessment of safety data from combination therapy with statins and in diabetic populations.
Main Results:
- Niacin ER effectively modifies lipoprotein levels, comparable to niacin IR, with reduced flushing.
- Niacin ER is not associated with the hepatotoxicity seen with SR formulations.
- Combination therapy with statins and niacin ER showed no significant myopathy; diabetic patients experienced only mild effects on glycosylated hemoglobin.
Conclusions:
- Extended-release niacin (niacin ER) is an effective and safe therapeutic option for improving lipoprotein profiles.
- Niacin ER offers a favorable balance of efficacy and tolerability for managing dyslipidemia in diverse patient groups.
- Niacin ER represents a valuable advancement in niacin therapy for cardiovascular risk reduction.
Related Concept Videos
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...